Drug Manufacturers – Major
(LLY) Eli Lilly and Company Sees Positive Data on Diabetes Candidate
Eli Lilly and Company (LLY) recently announced top-line data on its type II diabetes candidate, dulaglutide. The company said that dulaglutide met its primary endpoint in two phase III studies (AWARD-2 and AWARD-4) which are a part...3May2013 | vitalstocks | Comments Off | Continued
(JNJ) Protect Yourself From Gold
Gold is supposed to act as a safe haven from crisis and a hedge against inflation. But lately, it hasn’t been either. You would think with the bombastic manchild leader in North Korea threatening nuclear Armageddon and the usual problems in the Middle East, investors would flock to gold....2May2013 | InvestmentU | Comments Off | Continued
(ABT) Abbott Laboratories Launches Automated Solution
Abbott Laboratories (ABT) recently announced that the company has launched ACCELERATOR a3600 – its next-generation track system to increase efficiency in laboratories. A laboratory automation track system, ACCELERATOR a3600...2May2013 | vitalstocks | Comments Off | Continued
(PFE) Grading the First Quarter Earnings Season – Earnings Preview
Grading the Q1 Earnings Season We have crossed the halfway mark in the Q1 earnings season, with results from 271 S&P 500 companies already out (as of Friday, April 26th). Please note that these 271 companies are more than just 54.2% of the index’s total membership –...2May2013 | vitalstocks | Comments Off | Continued
(PFE) Grading the Q1 Earnings Season – Earnings Preview
Grading the Q1 Earnings Season We have crossed the halfway mark in the Q1 earnings season, with results from 271 S&P 500 companies already out (as of Friday, April 26th). Please note that these 271 companies are more than just 54.2% of the index’s total membership –...27Apr2013 | vitalstocks | Comments Off | Continued
(NVS) Theravance – Glaxo Drug to Face FDA Panel
The US Food and Drug Administration (FDA) recently released briefing documents ahead of the review by its Pulmonary-Allergy Drugs Advisory Committee of the New Drug Application (NDA) of Theravance/Glaxo’s (THRX/...27Apr2013 | vitalstocks | Comments Off | Continued
(JNJ) BioLineRx to Start BL-8040 Study
BioLineRx (BLRX) recently received approval in the US for the initiation of a multi-center, open-label phase IIa study on BL-8040. BioLineRx is looking to develop BL-8040 for the treatment of acute myeloid leukemia (AML) and other...27Apr2013 | vitalstocks | Comments Off | Continued
(JNJ) Will Johnson & Johnson Miss on Earnings?
Johnson & Johnson (JNJ) is scheduled to report its first quarter 2013 results on Apr 16, 2013 before the opening bell. Last quarter, the company posted a 1.71% positive surprise. Let’s see how things are shaping up prior...23Apr2013 | vitalstocks | Comments Off | Continued
(MRK) Roche Teams Up with Ascletis
Roche (RHHBY) recently announced that it has entered into a collaboration agreement with Ascletis to develop and commercialize Roche’s candidate danoprevir in China for treating patients suffering from hepatitis-c virus (HCV). The...23Apr2013 | vitalstocks | Comments Off | Continued
(GSK) GlaxoSmithKline’s Flu Vaccine Approved
GlaxoSmithKline(GSK) recently announced the receipt of marketing authorization for its four-strain seasonal influenza vaccine in Germany and the UK. The vaccine will be marketed as Influsplit Tetra in Germany and Fluarix Tetra in the...18Apr2013 | vitalstocks | Comments Off | Continued
(SNY) Sanofi/Transgene Inks Immunotherapy Deal
Sanofi (SNY) recently entered into a collaboration Transgene for the production of immunotherapy products and creating of an industrial platform for the same. The platform will include Transgene’s candidates. Sanofi and Transgene,...11Apr2013 | vitalstocks | Comments Off | Continued
(MRK) Pharma & Biotech Stock Outlook – Apr 2013 – Zacks Analyst Interviews
The pharmaceutical industry has been showing signs of recovery from one of the biggest patent cliffs in recent times. The last few quarters saw major blockbusters like Merck’s (MRK) Singulair, Pfizer’s (PFE)...7Apr2013 | vitalstocks | Comments Off | Continued
(NVS) Novartis Drug Candidate Earns Good News
Novartis (NVS) recently announced that the US Food and Drug Administration (FDA) rendered Breakthrough Therapy designation to its pipeline candidate LDK378. The Breakthrough Therapy designation includes all the features involved...4Apr2013 | vitalstocks | Comments Off | Continued
(AZN) AstraZeneca to Revamp Research and Development Structure
AstraZeneca (AZN) recently announced that it plans to initiate strategic reforms in its research and development (R&D) segment. As per proposed plans, the company’s R&D activities will be primarily centered in three facilities...1Apr2013 | vitalstocks | Comments Off | Continued
(NVS) Novartis Announces Positive Drug Approval News
Novartis (NVS) recently announced that the European Commission (EC) has approved its drug llaris (canakinumab, ACZ885) for an additional indication. The EC cleared llaris for treating adults suffering from gouty arthritis (gout) –...13Mar2013 | vitalstocks | Comments Off | Continued
(SNY) Sanofi Diabetes Drug Under FDA Review
Sanofi (SNY) recently announced that the US Food and Drug Administration (FDA) has accepted the marketing application of its type II diabetes candidate, lixisenatide. The company is looking to get lixisenatide approved for the treatment...2Mar2013 | Shawn | Comments Off | Continued
(SNY) Sanofi’s Diabetes Drug Gets EU Nod
Recently, Sanofi (SNY) received encouraging news with the European Commission (EC) approving its diabetes candidate, Lyxumia (lixisenatide). The EC cleared Lyxumia for glycemic control in patients, above 18 years of age, suffering...18Feb2013 | Shawn | Comments Off | Continued
(ABT) AbbVie Provides 2013 Outlook
AbbVie (ABBV) recently confirmed its sales figures for 2012 and provided guidance for 2013 as an independent company. AbbVie came into existence earlier this year following its separation from Abbott Laboratories...18Feb2013 | Shawn | Comments Off | Continued
(SPPI) Spectrum Pharmaceuticals Acquires Apaziquone Rights
Spectrum Pharmaceuticals (SPPI) recently announced that it has regained development and commercial rights for apaziquone from Allergan Inc. (AGN). Spectrum Pharma...17Feb2013 | Shawn | Comments Off | Continued
(JNJ) MedTech Industry Stock Outlook – January 2013 – Zacks Analyst Interviews
We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide medical devices market. The US still holds the leading position with almost one-third of the market share. However, emerging economies like Brazil, Russia, India and China –...31Jan2013 | Shawn | Comments Off | Continued
(AZN) Management Expands at AstraZeneca
AstraZeneca (AZN) recently announced that the company has created seven positions in the senior executive team. At the same time, two senior roles were discontinued. We note that three of the seven newly created positions are...22Jan2013 | Shawn | Comments Off | Continued
(AEGR) Aegerion Pharmaceuticals Prices Stock Offering
Aegerion Pharmaceuticals, Inc. (AEGR) recently provided more details on its public offering. The offering is expected to close on Jan 16, 2013. The total offer consists of approximately 2.7 million shares to be issued at a...16Jan2013 | Shawn | Comments Off | Continued
(GSK) GlaxoSmithKline and Theravance Seek European Approval
GlaxoSmithKline (GSK) and Theravance, Inc. (THRX) recently announced the submission of a marketing application to the European Medicines Agency (EMA) for their pipeline...16Jan2013 | Shawn | Comments Off | Continued
(SNY) Sanofi Updates on Pipeline
Sanofi (SNY) recently provided an update on its pipeline. Sanofi boasts of a robust pipeline with 65 new molecular entities and vaccines in clinical development, of which 17 are in phase III development or under regulatory review. We...15Jan2013 | Shawn | Comments Off | Continued
(ABT) Abbott Laboratories’ ABSORB in Phase III Trial
Abbott Laboratories (ABT) recently announced that its Absorb Bioresorbable Vascular Scaffold (BVS) device has moved into a phase III study, ABSORB III, in the US. The randomized, controlled study will enroll 2,250 patients and...15Jan2013 | Shawn | Comments Off | Continued
(SNY) Sanofi Shares Remain Neutral
We are maintaining our Neutral recommendation on Sanofi (SNY). The stock carries a Zacks #3 Rank (Hold) in the short run. Sanofi reported third quarter 2012 business earnings of $1.05 per ADS, above the Zacks Consensus Estimate...1Jan2013 | Shawn | Comments Off | Continued
(BMY) Takeda Pharmaceutical Company Limited Terminates Amylin Agreement
Takeda Pharmaceutical Company Limited (TKPYY) recently announced that it has mutually terminated its worldwide agreement with Amylin Pharmaceuticals, Inc., a wholly-owned subsidiary of Bristol-Myers Squibb (BMY). Takeda...1Jan2013 | Shawn | Comments Off | Continued
(JNJ) Back to Neutral on Bayer
We are reverting to a Neutral recommendation on Bayer (BAYRY) as we believe that all the positive news that led to our previous Outperform recommendation on the stock are reflected in the current price. Bayer performed impressively...31Dec2012 | Shawn | Comments Off | Continued
(GSK) GlaxoSmithKline’s Influenza Vaccine Approved
GlaxoSmithKline (GSK) recently announced that it has received US Food and Drug Administration (FDA) approval for its influenza vaccine, Fluarix Quadrivalent for the prevention of infl ...28Dec2012 | Shawn | Comments Off | Continued
(GSK) GlaxoSmithKline Anthrax Drug Gets FDA Nod
GlaxoSmithKline (GSK) recently announced that its inhalation anthrax candidate, raxibacumab, has received US Food and Drug Administration (FDA) approval. Raxibacumab was approved for inhalational anthrax caused by bacillus anthracis...23Dec2012 | Shawn | Comments Off | Continued